OGN Stock Recent News

OGN LATEST HEADLINES

OGN Stock News Image - businesswire.com

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces the appointment of Ramona A. Sequeira to the company's Board of Directors, effective July 1, 2025.

businesswire.com 2025 Apr 15
OGN Stock News Image - businesswire.com

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon will host Q1 2025 earnings results webcast and conference call on May 1, 2025.

businesswire.com 2025 Apr 15
OGN Stock News Image - zacks.com

Organon (OGN) closed the most recent trading day at $11.30, moving +1.07% from the previous trading session.

zacks.com 2025 Apr 14
OGN Stock News Image - zacks.com

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

zacks.com 2025 Apr 14
OGN Stock News Image - zacks.com

Organon (OGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

zacks.com 2025 Apr 10
OGN Stock News Image - zacks.com

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

zacks.com 2025 Apr 03
OGN Stock News Image - zacks.com

Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

zacks.com 2025 Apr 02
OGN Stock News Image - zacks.com

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

zacks.com 2025 Apr 01
OGN Stock News Image - businesswire.com

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announced it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion.

businesswire.com 2025 Apr 01
OGN Stock News Image - businesswire.com

SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)--Henlius and Organon announced the European Medicines Agency validates filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11.

businesswire.com 2025 Mar 28
10 of 50